Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07799220 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma

Name: A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma — clinical trial record (NCT07799220)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorMemorial Sloan Kettering Cancer Center

Started2026-09

View on ClinicalTrials.gov ↗

Memorial Sloan Kettering Cancer Center

779 trials monitored

See 100 trials at risk

Mantle Cell Lymphoma

251 trials monitored

See 18 trials at risk

The researchers are doing this study to find out whether the combination of zanubrutinib, obinutuzumab, and sonrotoclax (BOSon) is an effective treatment approach for people with mantle cell lymphoma (MCL).

Trial Details

NCT Number	NCT07799220
Lead Sponsor	Memorial Sloan Kettering Cancer Center Collaborators: BeOne Medicines, Genentech, Inc.
Conditions	Mantle Cell Lymphoma
Enrollment	45 participants
Start Date	2026-09
Primary Completion	2028-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-09-10